SOLTF (Nxera Pharma Co) NonCurrent Deferred Liabilities: $0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SOLTF Nxera Pharma Co Ltd SOLTF
83 GF Score
Price $5.99
GF Value $7.87
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co NonCurrent Deferred Liabilities?

Nxera Pharma Co SOLTF -0.17% 83 NonCurrent Deferred Liabilities is $0.0 Mil as of Mar. 2026. GuruFocus rates SOLTF with a GF Score™ of 83/100 and a GF Value™ of $7.87 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Nxera Pharma Co's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.0 Mil.

Nxera Pharma Co NonCurrent Deferred Liabilities Related Terms

Nxera Pharma Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co NonCurrent Deferred Liabilities Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nxera Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SOLTF
83GF Score
Nxera Pharma Co Ltd SOLTF
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.0 Mil mean?
Nxera Pharma Co (SOLTF) has a NonCurrent Deferred Liabilities of $0.0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's NonCurrent Deferred Liabilities too high?
Nxera Pharma Co's current NonCurrent Deferred Liabilities is $0.0 Mil. Overall, Nxera Pharma Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Nxera Pharma Co's NonCurrent Deferred Liabilities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current NonCurrent Deferred Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.87, compared to a current price of $5.99 — trading 23.9% below its estimated fair value. The current NonCurrent Deferred Liabilities is $0.0 Mil. Nxera Pharma Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current NonCurrent Deferred Liabilities is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (SOLTF) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of $5.99 is trading 23.9% below its estimated GF Value™ of $7.87. GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.

Key valuation signals for SOLTF:

  • NonCurrent Deferred Liabilities: $0.0 Mil
  • GF Value™: $7.87 vs. price of $5.99 (23.9% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Other Exchanges 4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
83GF Score

Get the complete analysis for SOLTF

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.99
Price
$7.87
GF Value